PhasED-Seq

Foresight Diagnostics to Present a Vision of the New Standard of Lymphoma MRD Detection at the 16th International Conference on Malignant Lymphoma

Retrieved on: 
Thursday, June 17, 2021
Biotechnology, Health, Genetics, Pharmaceutical, Oncology, Clinical medicine, Medicine, DNA, Medical specialties, Lymphoma, Anatomical pathology, Circulating tumor DNA, Neoplasms, Diffuse large B-cell lymphoma, CAPP-Seq, Foresight Diagnostics, PhasED-Seq, FORESIGHT DIAGNOSTICS, PHASED-SEQ

The oral presentation demonstrates the utility of Foresight Diagnostics proprietary PhasED-Seq technology to improve MRD detection rates in DLBCL patients in low-disease burden settings.

Key Points: 
  • The oral presentation demonstrates the utility of Foresight Diagnostics proprietary PhasED-Seq technology to improve MRD detection rates in DLBCL patients in low-disease burden settings.
  • We believe that such early detection constitutes the future standard for ctDNA-guided patient monitoring and treatment in the clinic and for drug development applications.
  • Circulating tumor DNA (ctDNA) detection has prognostic value in DLBCL and has the potential to change the management of lymphoma in the clinic.
  • But detection is still challenging in low-disease burden states with existing methods, such as MRD detection at the end of therapy.